Hypercholesterolemia Market Report 2026

The hypercholesterolemia market size has grown rapidly in recent years. It will grow from $18.61 billion in 2025 to $21.24 billion in 2026 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to rising prevalence of cardiovascular diseases, widespread use of statins as first-line therapy, increasing sedentary lifestyles, high consumption of unhealthy diets, established clinical guidelines for cholesterol management.

The hypercholesterolemia market size is expected to see rapid growth in the next few years. It will grow to $35.59 billion in 2030 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to growing awareness of familial hypercholesterolemia, increasing adoption of biologic therapies, rising aging population, advancements in lipid profiling diagnostics, expanding preventive healthcare initiatives. Major trends in the forecast period include increasing adoption of pcsk9 inhibitors, growing emphasis on early screening and diagnosis, rising demand for combination lipid-lowering therapies, shift toward injectable long-acting treatments, expanding role of preventive cardiovascular care.

The rising prevalence of cardiovascular diseases is expected to drive the growth of the hypercholesterolemia market in the coming years. Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels. Factors such as unhealthy diets, physical inactivity, increasing obesity rates, chronic stress, aging populations, and the presence of conditions like hypertension and diabetes are contributing to the rise in CVDs. Treatments for hypercholesterolemia help patients by lowering LDL cholesterol levels, reducing arterial plaque buildup, improving blood flow, and decreasing the risk of heart attacks, strokes, and other cardiovascular complications. For example, in October 2024, the Centers for Disease Control and Prevention (CDC) reported that approximately 805,000 people in the United States experience a heart attack each year, of which 605,000 are first-time events and 200,000 occur in individuals with a prior history of heart attacks. Consequently, the increasing incidence of cardiovascular diseases is expected to propel the hypercholesterolemia market.

Key companies in the hypercholesterolemia market are developing innovative therapies, including triple-combination drugs, to enhance treatment effectiveness and patient adherence. A triple-combination drug combines three active ingredients into a single formulation, such as a tablet or capsule. For instance, in February 2025, Celltrion Pharm, Inc., a South Korea-based pharmaceutical company, launched Amrozet Tablet, a therapy for hypertension and hyperlipidemia. The drug combines amlodipine, a calcium channel blocker for hypertension; rosuvastatin, a statin for lowering cholesterol; and ezetimibe, which reduces cholesterol absorption in the intestines. Amrozet is available in four dosage combinations - 5/5/10 mg, 5/10/10 mg, 10/5/10 mg, and 10/10/10 mg - and is indicated for primary hypercholesterolemia, hypertension, myocardial ischemia, chronic stable angina, and vasospastic angina. It also helps reduce hospitalization risk for angina and heart surgery in patients with documented coronary artery disease.

In August 2023, HDL Therapeutics, Inc., a US-based biotechnology company, merged with Swiftmerge Acquisition Corp. to accelerate growth in the hypercholesterolemia market. This merger enables HDL Therapeutics to enhance the commercialization of its FDA-approved Plasma Delipidation System (PDS-2), which is used to treat patients with homozygous familial hypercholesterolemia (HoFH). Swiftmerge Acquisition Corporation is a US-based special purpose acquisition company (SPAC) focused on supporting therapies for HoFH.

Major companies operating in the hypercholesterolemia market are Pfizer Inc., Merck & Co Inc., Abbvie Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Viatris Inc., Aegerion Pharmaceuticals Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Lupin Limited, Ionis Pharmaceuticals Inc., NewAmsterdam Pharma N.V., HDL Therapeutics Inc.

North America was the largest region in the hypercholesterolemia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hypercholesterolemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hypercholesterolemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the hypercholesterolemia market by increasing costs for imported active pharmaceutical ingredients and biologic components used in advanced lipid-lowering therapies. These effects are most evident for injectable biologics such as PCSK9 inhibitors, particularly in regions dependent on global pharmaceutical supply chains like North America and Europe. At the same time, tariffs are encouraging local manufacturing, generic drug development, and diversified sourcing strategies, supporting improved long-term affordability and supply security.

The hypercholesterolemia market research report is one of a series of new reports that provides hypercholesterolemia market statistics, including hypercholesterolemia industry global market size, regional shares, competitors with a hypercholesterolemia market share, detailed hypercholesterolemia market segments, market trends and opportunities, and any further data you may need to thrive in the hypercholesterolemia industry. This hypercholesterolemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hypercholesterolemia is characterized by abnormally high levels of cholesterol in the blood, particularly low-density lipoprotein (LDL) cholesterol, which increases the risk of atherosclerosis and cardiovascular events such as heart attacks and strokes. Its development is influenced by genetic predisposition, unhealthy diet, sedentary lifestyle, and underlying health conditions like diabetes or hypothyroidism.

The main types of hypercholesterolemia are genetic and acquired. Genetic forms, such as familial hypercholesterolemia, result from inherited mutations that affect cholesterol metabolism. Treatment options include statins, bile acid resins, niacin, PCSK9 inhibitors, cholesterol absorption inhibitors, fibric acid derivatives, and other therapies. These medications are administered orally or via injection and are distributed through hospital pharmacies, retail pharmacies, and other channels. End users include hospitals, specialty clinics, home healthcare providers, and other healthcare facilities.

The hypercholesterolemia market consists of sales of omega-3 fatty acid supplements, atorvastatin, and simvastatin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.